Leerink Partners Downgrades Gilead Sciences to Market Perform, Lowers Price Target to $127

Benzinga · 2d ago
Leerink Partners analyst Daina Graybosch downgrades Gilead Sciences (NASDAQ:GILD) from Outperform to Market Perform and lowers the price target from $146 to $127.